AAPL 250.9362 1.1636% MSFT 439.85 0.5624% NVDA 132.26 2.5987% GOOGL 190.36 1.0403% GOOG 191.585 0.7547% AMZN 224.7026 1.8967% META 605.1 1.3245% AVGO 221.57 -0.9167% TSLA 434.8 -1.211% TSM 195.3 -0.133% LLY 758.87 -0.7637% V 315.9 1.9756% JPM 234.325 1.7168% UNH 493.79 -1.1867% NVO 103.7 -2.1329% WMT 93.89 0.3634% LVMUY 130.52 0.7721% XOM 105.67 -0.7048% LVMHF 649.5 0.6649% MA 526.755 1.3068%
Last update at 2024-12-19T18:54:00Z
New PBM Legislation Sparks Healthcare Selloff on Wall Street
Wed 11 Dec 24, 10:35 PMLawmakers Plot to Force Health Insurers to Sell Off Pharmacies
Wed 11 Dec 24, 01:00 PMLarry Robbins' Strategic Acquisition in Foley Trasimene Acquisition Corp
Mon 21 Oct 24, 03:01 PMCigna Restarts Talks To Buy Fallen Star Humana; 2024 Election Is Key
Mon 21 Oct 24, 02:40 PMCigna slips and Humana gains on report of renewed merger talks
Mon 21 Oct 24, 11:13 AMCigna Healthcare Commits $600,000 To Reduce Food Insecurity Among Seniors
Mon 21 Oct 24, 10:00 AMGoldman Sachs: The Cigna Group (NYSE:CI) Is A Stock With High Consensus ROE
Sat 19 Oct 24, 08:52 PMZacks Industry Outlook Highlights UnitedHealth, The Cigna, Humana and Molina Healthcare
Fri 18 Oct 24, 01:14 PMPharmacy Retailer CVS Health Backs Away From Annual Forecast, Names New CEO
Fri 18 Oct 24, 11:14 AM| Breakdown | 2022-12-31 | 2021-12-31 | 2020-12-31 | 2019-12-31 | 2018-12-31 |
|---|---|---|---|---|---|
| Type | yearly | yearly | yearly | yearly | yearly |
| Date | 2022-12-31 | 2021-12-31 | 2020-12-31 | 2019-12-31 | 2018-12-31 |
| Income before tax | 8353.00M | 6782.00M | 10868.00M | 6570.00M | 3581.00M |
| Minority interest | 78.00M | 50.00M | 31.00M | 41.00M | 44.00M |
| Net income | 6668.00M | 5365.00M | 8458.00M | 5104.00M | 2637.00M |
| Selling general administrative | 12738.00M | 12242.00M | 14072.00M | 14053.00M | 11934.00M |
| Selling and marketing expenses | - | - | - | - | - |
| Gross profit | 148436.00M | 140710.00M | 127867.00M | 122924.00M | 21041.00M |
| Reconciled depreciation | 2937.00M | 2923.00M | 2802.00M | 3651.00M | 695.00M |
| Ebit | 9503.00M | 8352.00M | 8714.00M | -96545.00000M | 4070.00M |
| Ebitda | 12440.00M | 11275.00M | 11516.00M | -92894.00000M | 4765.00M |
| Depreciation and amortization | 2937.00M | 2923.00M | 2802.00M | 3651.00M | 695.00M |
| Non operating income net other | 434.00M | -1349.00000M | 2566.00M | -1684.00000M | -498.00000M |
| Operating income | 9503.00M | 8352.00M | 8714.00M | -96545.00000M | 4070.00M |
| Other operating expenses | 171668.00M | 167490.00M | 149709.00M | 147173.00M | 44988.00M |
| Interest expense | 1228.00M | 1208.00M | 1438.00M | 1682.00M | 498.00M |
| Tax provision | 1607.00M | 1367.00M | 2379.00M | 1450.00M | 939.00M |
| Interest income | 1228.00M | 1208.00M | 1438.00M | 1682.00M | 271.00M |
| Net interest income | -1228.00000M | -1208.00000M | -1438.00000M | -1682.00000M | -498.00000M |
| Extraordinary items | - | - | - | 0.00000M | 4.00M |
| Non recurring | - | - | - | - | - |
| Other items | - | - | - | - | - |
| Income tax expense | 1607.00M | 1367.00M | 2379.00M | 1450.00M | 935.00M |
| Total revenue | 180642.00M | 174272.00M | 160577.00M | 153743.00M | 48569.00M |
| Total operating expenses | 13186.00M | -288953.00000M | -257509.00000M | -250288.00000M | 44490.00M |
| Cost of revenue | 32206.00M | 33562.00M | 32710.00M | 30819.00M | 27528.00M |
| Total other income expense net | -1150.00000M | 121463.00M | 107800.00M | 103115.00M | 5479.00M |
| Discontinued operations | - | - | - | - | - |
| Net income from continuing ops | 6668.00M | 5415.00M | 8489.00M | 5120.00M | 2646.00M |
| Net income applicable to common shares | 6668.00M | 5365.00M | 8458.00M | 5104.00M | 2637.00M |
| Preferred stock and other adjustments | - | - | - | - | - |
| Breakdown | 2023-12-31 | 2022-12-31 | 2021-12-31 | 2020-12-31 | 2019-12-31 |
|---|---|---|---|---|---|
| Type | yearly | yearly | yearly | yearly | yearly |
| Date | 2023-12-31 | 2022-12-31 | 2021-12-31 | 2020-12-31 | 2019-12-31 |
| Total assets | 152761.00M | 143932.00M | 154889.00M | 155451.00M | 155774.00M |
| Intangible assets | 30863.00M | 32492.00M | 34102.00M | 35179.00M | 36562.00M |
| Earning assets | - | - | - | - | - |
| Other current assets | 6162.00M | 2201.00M | 12260.00M | 2261.00M | 11849.00M |
| Total liab | 106410.00M | 98981.00M | 107705.00M | 105065.00M | 110395.00M |
| Total stockholder equity | 46223.00M | 44872.00M | 47112.00M | 50321.00M | 45338.00M |
| Deferred long term liab | - | 7751.00M | 8346.00M | 8939.00M | 9387.00M |
| Other current liab | 37388.00M | -10768.00000M | -9200.00000M | -22199.00000M | -21058.00000M |
| Common stock | 4.00M | 4.00M | 4.00M | 4.00M | 4.00M |
| Capital stock | 4.00M | 4.00M | 4.00M | 4.00M | 4.00M |
| Retained earnings | 41652.00M | 37874.00M | 32593.00M | 28575.00M | 20162.00M |
| Other liab | - | 29306.00M | 33008.00M | 39498.00M | 37899.00M |
| Good will | 44259.00M | 45811.00M | 45811.00M | 44648.00M | 44602.00M |
| Other assets | - | 32160.00M | 43965.00M | 41184.00M | 47884.00M |
| Cash | 7822.00M | 5924.00M | 5081.00M | 10182.00M | 4619.00M |
| Cash and equivalents | - | 5924.00M | 5081.00M | 10182.00M | 4619.00M |
| Total current liabilities | 48716.00M | 10768.00M | 9200.00M | 22199.00M | 21058.00M |
| Current deferred revenue | - | - | - | - | - |
| Net debt | 23108.00M | 25169.00M | 28589.00M | 22737.00M | 32788.00M |
| Short term debt | 2775.00M | 2993.00M | 2545.00M | 3374.00M | 5514.00M |
| Short long term debt | 2775.00M | 2993.00M | 2545.00M | 3374.00M | 5514.00M |
| Short long term debt total | 30930.00M | 31093.00M | 33670.00M | 32919.00M | 37407.00M |
| Other stockholder equity | 6431.00M | 8389.00M | 15399.00M | 22603.00M | 26113.00M |
| Property plant equipment | - | 4149.00M | 3692.00M | 4205.00M | 4953.00M |
| Total current assets | 37351.00M | 28790.00M | 26096.00M | 28904.00M | 21372.00M |
| Long term investments | 925.00M | 16288.00M | 18438.00M | 23262.00M | 937.00M |
| Net tangible assets | - | -33365.00000M | -32801.00000M | -29448.00000M | -35826.00000M |
| Short term investments | 925.00M | 905.00M | 920.00M | 1331.00M | 937.00M |
| Net receivables | 17722.00M | 21961.00M | 20095.00M | 17391.00M | 15816.00M |
| Long term debt | 28155.00M | 28034.00M | 31097.00M | 29545.00M | 31832.00M |
| Inventory | 5645.00M | 4777.00M | 3722.00M | 3165.00M | 2661.00M |
| Accounts payable | 8553.00M | 7775.00M | 6655.00M | 18825.00M | 15544.00M |
| Total permanent equity | - | - | - | - | - |
| Noncontrolling interest in consolidated entity | - | 13.00M | 18.00M | 7.00M | 6.00M |
| Temporary equity redeemable noncontrolling interests | - | - | - | - | - |
| Accumulated other comprehensive income | -1864.00000M | -1395.00000M | -884.00000M | -861.00000M | -941.00000M |
| Additional paid in capital | - | - | - | - | - |
| Common stock total equity | - | 4.00M | 4.00M | 4.00M | 4.00M |
| Preferred stock total equity | - | - | - | - | - |
| Retained earnings total equity | - | 37874.00M | 32593.00M | 28575.00M | 20162.00M |
| Treasury stock | - | -21844.00000M | -14175.00000M | -6372.00000M | -2193.00000M |
| Accumulated amortization | - | - | - | - | - |
| Non currrent assets other | 18238.00M | -82982.00000M | -84828.00000M | -85363.00000M | -86518.00000M |
| Deferred long term asset charges | - | - | - | - | - |
| Non current assets total | 115410.00M | 82982.00M | 84828.00M | 85363.00M | 86518.00M |
| Capital lease obligations | - | - | - | - | - |
| Long term debt total | - | 28100.00M | 31125.00M | 29545.00M | 31893.00M |
| Breakdown | 2023-12-31 | 2022-12-31 | 2021-12-31 | 2020-12-31 | 2019-12-31 |
|---|---|---|---|---|---|
| Type | yearly | yearly | yearly | yearly | yearly |
| Date | 2023-12-31 | 2022-12-31 | 2021-12-31 | 2020-12-31 | 2019-12-31 |
| Investments | -5174.00000M | -587.00000M | -765.00000M | -443.00000M | -4832.00000M |
| Change to liabilities | - | 1865.00M | -77.00000M | 2187.00M | 1918.00M |
| Total cashflows from investing activities | - | 3098.00M | -3611.00000M | 2976.00M | -734.00000M |
| Net borrowings | - | -500.00000M | 800.00M | -4796.00000M | -5175.00000M |
| Total cash from financing activities | -4294.00000M | -11240.00000M | -8212.00000M | -8533.00000M | -7187.00000M |
| Change to operating activities | - | 2338.00M | 2605.00M | 4252.00M | -136.00000M |
| Net income | 5164.00M | 6746.00M | 5415.00M | 8489.00M | 5120.00M |
| Change in cash | 2361.00M | 428.00M | -4697.00000M | 4834.00M | 1556.00M |
| Begin period cash flow | 5976.00M | 5548.00M | 10245.00M | 5411.00M | 3855.00M |
| End period cash flow | 8337.00M | 5976.00M | 5548.00M | 10245.00M | 5411.00M |
| Total cash from operating activities | 11813.00M | 8656.00M | 7191.00M | 10350.00M | 9485.00M |
| Issuance of capital stock | 185.00M | 389.00M | 326.00M | 376.00M | 224.00M |
| Depreciation | 3035.00M | 2937.00M | 2923.00M | 2802.00M | 3651.00M |
| Other cashflows from investing activities | - | 4393.00M | -3611.00000M | 3419.00M | 5148.00M |
| Dividends paid | 1450.00M | 1384.00M | 1341.00M | 15.00M | 681.00M |
| Change to inventory | -868.00000M | -1055.00000M | 143.00M | 30.00M | 149.00M |
| Change to account receivables | -2202.00000M | -2275.00000M | -3232.00000M | -1266.00000M | -990.00000M |
| Sale purchase of stock | -2284.00000M | -7607.00000M | -7742.00000M | -4042.00000M | -1987.00000M |
| Other cashflows from financing activities | -469.00000M | -2138.00000M | 999.00M | 1342.00M | -252.00000M |
| Change to netincome | - | -1647.00000M | -225.00000M | -4539.00000M | -488.00000M |
| Capital expenditures | 1573.00M | 1295.00M | 1154.00M | 1094.00M | 1050.00M |
| Change receivables | - | -2275.00000M | -3232.00000M | -1266.00000M | -990.00000M |
| Cash flows other operating | - | 2085.00M | 2027.00M | 3181.00M | 125.00M |
| Exchange rate changes | - | - | - | - | - |
| Cash and cash equivalents changes | - | 514.00M | -4632.00000M | 4793.00M | 1564.00M |
| Change in working capital | 3488.00M | 620.00M | -872.00000M | 3598.00M | 643.00M |
| Stock based compensation | 286.00M | 264.00M | 268.00M | 289.00M | 299.00M |
| Other non cash items | 1499.00M | -1431.00000M | 141.00M | 199.00M | 561.00M |
| Free cash flow | 10240.00M | 7361.00M | 6037.00M | 9256.00M | 8435.00M |
Sector: Healthcare Industry: Healthcare Plans
| Company | Change (USD) | Price (USD) | Trailing PE (x) | Forward PE (x) | Price Sales TTM (x) | Price to Book Value (x) | Enterprise Value to Revenue (x) | |
|---|---|---|---|---|---|---|---|---|
| CI Cigna Corp |
-4.215 1.49% | 278.19 | 30.25 | 10.09 | 0.39 | 2.10 | 0.50 | |
| UNH UnitedHealth Group Incorporated |
-5.93 1.19% | 493.79 | 22.57 | 18.38 | 1.33 | 5.65 | 1.38 | 13.97 |
| ELV Elevance Health Inc |
1.20 0.33% | 367.46 | 18.00 | 12.66 | 0.65 | 2.87 | 0.74 | |
| CVS CVS Health Corp |
-0.82 1.81% | 44.46 | 12.06 | 9.08 | 0.29 | 1.34 | 0.47 | 8.96 |
| HUM Humana Inc |
-5.62 2.34% | 234.23 | 19.16 | 14.60 | 0.56 | 3.37 | 0.53 |
The Cigna Group, together with its subsidiaries, provides insurance and related products and services in the United States. Its Evernorth Health Services segment provides a range of coordinated and point solution health services, including pharmacy benefits, home delivery pharmacy, specialty pharmacy, distribution, and care delivery and management solutions to health plans, employers, government organizations, and health care providers. The company's Cigna Healthcare segment offers medical, pharmacy, behavioral health, dental, and other products and services for insured and self-insured customers; Medicare Advantage, Medicare Supplement, and Medicare Part D plans for seniors, as well as individual health insurance plans; and health care coverage in its international markets, as well as health care benefits for mobile individuals and employees of multinational organizations. In addition, it offers permanent insurance contracts sold to corporations to provide coverage on the lives of certain employees for financing employer-paid future benefit obligations. The company distributes its products and services through insurance brokers and consultants; directly to employers, unions and other groups, or individuals; and private and public exchanges. The company was formerly known as Cigna Corporation and changed its name to The Cigna Group in February 2023. The Cigna Group was founded in 1792 and is headquartered in Bloomfield, Connecticut.
900 Cottage Grove Road, Bloomfield, CT, United States, 06002
| Name | Title | Year Born |
|---|---|---|
| Mr. David Michael Cordani | Pres, CEO & Chair of the Board | 1965 |
| Mr. Brian C. Evanko | Exec. VP & CFO | 1977 |
| Ms. Nicole Susan Jones | Exec. VP & Gen. Counsel | 1970 |
| Mr. Eric Paul Palmer | Pres & CEO of Evernorth | 1976 |
| Mr. Paul Sanford | Exec. VP of Operations | 1968 |
| Ms. Mary Terese Agoglia Hoeltzel CPA | Sr. VP of Tax & Chief Accounting Officer | NA |
| Ms. Noelle K. Eder | Exec. VP & Global Chief Information Officer | 1970 |
| Mr. Ralph Giacobbe | Sr. VP & Head of Investor Relations | NA |
| Mr. Everett Neville | Exec. VP of Strategy, Corp. Devel. & Solutions | 1965 |
| Ms. Cynthia Ryan | Exec. VP & Chief HR Officer | 1974 |
Disclaimer - This information, including any data, is sourced from Unicorn Data Services SAS, trading as EOD Historical Data (“EODHD”) on ‘as is’ basis, using their API. The information and data provided on this page, as well as via the API, are not guaranteed to be real-time or accurate. In some cases, the data may include analyst ratings or recommendations sourced through the EODHD API, which are intended solely for general informational purposes.
This information does not consider your personal objectives, financial situation, or needs. Kalkine does not assume any responsibility for any trading losses you might incur as a result of using this information, data, or any analyst rating or recommendation provided. Kalkine will not accept any liability for any loss or damage resulting from reliance on the information, including but not limited to data, quotes, charts, analyst ratings, recommendations, and buy/sell signals sourced via the API.
Please be fully informed about the risks and costs associated with trading in the financial markets, as it is one of the riskiest forms of investment. Kalkine does not provide any warranties regarding the information on this page, including, without limitation, warranties of merchantability or fitness for a particular purpose or use.
US 
AU
UK
CA
NZ
Please wait processing your request...